World Health Organization Issues Concern Over Acute Shortage of Obesity Jabs
Less than one in 10 patients who could benefit from GLP-1 drugs like Wegovy have access to them, warns the World Health Organization as it issues its first advice on the therapies.
With over a billion people worldwide currently obese, it is calling for increased and just availability to this class of drugs.
Based on estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"Our latest guidance acknowledges that excess weight is a chronic disease that can be treated with comprehensive and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are significant hurdles to broad availability to the jabs that can aid individuals in losing considerable weight, notes the agency.
Skinny Jab Shortage
Despite the present best projected scenario, the production of GLP-1 therapies would only suffice for around 100 million people – less than 10% of the global need, per the WHO.
The recommendation urges countries and companies to widen availability, by approaches including voluntary licensing.
A patent on a key compound – the main component of a leading brand – is scheduled to end in a number of nations in 2026.
The Way Weight-Loss Drugs Operate
These medications imitate a biological compound to reduce digestion speed, suppress the appetite and boost the sense of being full so users consume fewer calories.
Individuals typically see weight reduction within a few weeks of commencing the regular doses.
Evidence indicates users may put most of the weight back on a year later of halting the medication, because their typical appetite come back.
Being carrying excess weight elevates your likelihood for contracting health problems, such as diabetes, cardiovascular issues, stroke, and certain malignancies.
Excess weight affects people in all nations and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.
